Naloxone efficacy testing for polysubstance overdose reversal
Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression — In Vivo Validation — Solicitation b587aac3a76a4528bd4298359acde021, issued by Federal (Maryland place-of-performance).
In plain English
The FDA is seeking research to validate how well naloxone reverses respiratory depression caused by multiple drug combinations in preclinical studies. This in-vivo assessment will help determine naloxone's adequacy against polysubstance overdoses. Work is based in Maryland.
Key facts
- Issuing agency
- Federal (Maryland place-of-performance)
- Solicitation number
- b587aac3a76a4528bd4298359acde021
- Type
- Presolicitation
- Posted
- Aug 26, 2026
- Response deadline
- Sep 10, 2026, 3:00 PM EDT
Official description
Solicitation #75F40126Q00382. Issued by HEALTH AND HUMAN SERVICES, DEPARTMENT OF › FOOD AND DRUG ADMINISTRATION › FDA OFFICE OF ACQ GRANT SVCS. NAICS 541714. Product/Service Code AN12. Set-aside: No Set aside used.
Respond to this bid
This solicitation is administered by the issuing agency through its samgov procurement portal. Submission happens there, not on SledAtlas.
The direct link to the source posting is included with a free SledAtlas account — coming soon. Join the waitlist on the home page to get access at launch.